EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC-ND 4.0

Pharmacokinetics and Safety of Clofazimine in Women With Rifampicin-resistant Tuberculosis During Pregnancy and the Postpartum Period: Results From IMPAACT P1026s

Jennifer A Hughes iD, Flynn McMorrow, Kristina M Brooks iD, Mauricio Pinilla, Lee Fairlie iD, James S Ngocho iD, Alice Stek, Brookie M Best iD, Mark Mirochnick, Lubbe Wiesner iD, Kathleen George, Kevin Knowles und 7 weitere

The Journal of Infectious Diseases · 17.01.2026 · 233 (1) · 16-26

DOI: 10.1093/infdis/jiaf504 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift The Journal of Infectious Diseases, online erschienen am 30.10.2025. Verfasst von Jennifer A Hughes und 18 weiteren Autor:innen. Beteiligte Einrichtung: Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, Sout…. Hauptthemen laut MEDLINE: Clofazimine, Tuberculosis, Multidrug-Resistant, Pregnancy Complications, Infectious, Antitubercular Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: IMPAACT SDMC, The University of Cape Town Clinical PK Laboratory, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

There are no published data on clofazimine pharmacokinetics during pregnancy, and safety data are limited. We present data from pregnant and postpartum women receiving clofazimine for treatment of rifampicin-resistant tuberculosis (RR-TB).

Methods

IMPAACT P1026s was an observational study to assess the pharmacokinetics of tuberculosis and/or antiretroviral drugs during pregnancy. Between 2017 and 2019, pregnant women receiving ≥2 second-line antituberculosis drugs in routine care were enrolled in the second or third trimester and had intensive pharmacokinetic sampling at least once during pregnancy, and 2–8 weeks postpartum. Pharmacokinetic parameters were estimated using noncompartmental methods and compared between the antepartum and postpartum periods using geometric mean ratios (GMR) with 90% confidence intervals (CIs) and the Wilcoxon signed rank test for paired data.

Results

Eleven pregnant women from South Africa, 7 (64%) with HIV, were receiving clofazimine (100 mg daily) at enrollment, of which 82% received clofazimine for more than 8 weeks prior to pharmacokinetic evaluation. Nine (82%) women continued treatment postpartum. Peak plasma concentrations and area-under-the-concentration–time-curve over 12 hours were comparable to historical clofazimine pharmacokinetic data in nonpregnant women with RR-TB but were approximately 30% higher in the third trimester of pregnancy compared to the postpartum period. Eight women and 8 infants experienced at least one severe adverse event while on study but direct relatedness to clofazimine was considered unlikely.

Conclusions

Overall, antepartum and postpartum clofazimine exposures were comparable to those reported in nonpregnant women with RR-TB. Exposures were lower than expected in the postpartum period, particularly compared with the third trimester of pregnancy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ClofazimineTuberculosis, Multidrug-ResistantPregnancy Complications, InfectiousAntitubercular AgentsHumansFemalePregnancyAdultRifampinPostpartum PeriodSouth AfricaYoung AdultHIV Infections

Stichwörter der Autor:innen

clofaziminepharmacokineticspregnancyrifampicin-resistanttuberculosis

Substanzen

ClofazimineRifampinAntitubercular Agents

Autor:innen und Institutionen

  • Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
  • Center for Biostatistics in AIDS Research, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA.
  • Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
  • Wits RHI, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
  • Department of Epidemiology and Applied Biostatistics, KCMC University, Moshi, Tanzania.
  • Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, University of Southern California School of Medicine, Los Angeles, California, USA.

ORCID-Profile: Jennifer A Hughes, Kristina M Brooks, Lee Fairlie, James S Ngocho, Brookie M Best, Lubbe Wiesner, Eric Decloedt, Ahizechukwu C Eke

Förderung

  • IMPAACT SDMC
  • The University of Cape Town Clinical PK Laboratory
  • NIH HHS
  • NIAID NIH HHS
  • International Maternal Pediatric Adolescent AIDS Clinical Trials
  • NICHD NIH HHS
  • National Institute of Allergy and Infectious Diseases
  • IMPAACT

Zitieren

APA

Hughes, J. A., McMorrow, F., Brooks, K. M., Pinilla, M., Fairlie, L., Ngocho, J. S., Stek, A., Best, B. M., Mirochnick, M., Wiesner, L., George, K., Knowles, K., Browning, R., DeYampert, T., Hesseling, A. C., Decloedt, E., Shapiro, D. E., Eke, A. C., & IMPAACT P1026s Protocol Team (2026). Pharmacokinetics and Safety of Clofazimine in Women With Rifampicin-resistant Tuberculosis During Pregnancy and the Postpartum Period: Results From IMPAACT P1026s. The Journal of Infectious Diseases, 233(1), 16-26. https://doi.org/10.1093/infdis/jiaf504

Vancouver

Hughes JA, McMorrow F, Brooks KM, Pinilla M, Fairlie L, Ngocho JS, et al. Pharmacokinetics and Safety of Clofazimine in Women With Rifampicin-resistant Tuberculosis During Pregnancy and the Postpartum Period: Results From IMPAACT P1026s. The Journal of Infectious Diseases. 2026;233(1):16-26. doi:10.1093/infdis/jiaf504

BibTeX
@article{Hughes2026,
  author = {Hughes, Jennifer A and McMorrow, Flynn and Brooks, Kristina M and Pinilla, Mauricio and Fairlie, Lee and Ngocho, James S and Stek, Alice and Best, Brookie M and Mirochnick, Mark and Wiesner, Lubbe and George, Kathleen and Knowles, Kevin and Browning, Renee and DeYampert, Tara and Hesseling, Anneke C and Decloedt, Eric and Shapiro, David E and Eke, Ahizechukwu C and IMPAACT P1026s Protocol Team, IMPAACT P1026s Protocol Team},
  title = {Pharmacokinetics and Safety of Clofazimine in Women With Rifampicin-resistant Tuberculosis During Pregnancy and the Postpartum Period: Results From IMPAACT P1026s},
  journal = {The Journal of Infectious Diseases},
  year = {2026},
  volume = {233},
  number = {1},
  pages = {16--26},
  doi = {10.1093/infdis/jiaf504}
}
Kostenlos starten →